Menu
Menu
Menu
Menu
Our pipeline showcases a strategic mix of proprietary products and in-licensed rare disease therapies, highlighting our commitment to improving patient related outcomes through scientific innovation and strategic partnerships.
Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis. Binosto® is an effervescent tablet to be dissolved in half a glass of water and to be taken once a week.
EffRx developed Binosto® from start to finish, including benefit assessment, formulation, clinical development, FDA and European approval, licensing the product for commercialization to national & regional partners around the world.
The approximately 30 marketing authorizations obtained worldwide and the successful launch in as many territories provide an important proof-of-concept of EffRx’s go-to-market capabilities.
Alkindi® is an immediate-release hydrocortisone preparation specifically designed to meet the needs of pediatric patients with adrenal insufficiency.
Efmody® is a modified-release preparation of hydrocortisone specifically designed for the treatment of patients with CAH (Congenital Adrenal Hyperplasia), a rare condition caused by a genetic deficiency of adrenal enzymes.
Miglustat Dipharma® is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids. Its therapeutic areas are Lysosomal Storage Diseases.
